Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plamotamab - Xencor

Next Previous
X
Search
Drug Profile

Plamotamab - Xencor

Alternative Names: CD20 x CD3; XmAb 13676

Latest Information Update: 11 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Sep 2024 Xencor completes a phase I trial in Non-Hodgkin's lymphoma, Follicular lymphoma, Diffuse large B cell lymphoma and Chronic lymphocytic leukaemia (Second-line therapy or greater) in South Korea, France, USA and United Kingdom (Parenteral), before September 2024 (NCT02924402)
  • 09 Sep 2024 Xencor plans a phase Ib/IIa trial for Rheumatoid arthritis (Treatment-experienced) (Parenteral), in the first half of 2025
  • 13 Jun 2024 Janssen terminates its licence for Plamotamab

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top